Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

Sarah E. Messiah, PhD, MPH\textsuperscript{a,b}, Frances Brito, MS\textsuperscript{c}, Harold W. Kohl, III, PhD, MSPH\textsuperscript{d,e}, Stacia DeSantis, PhD\textsuperscript{c}, Melissa Valerio-Shewmaker, PhD\textsuperscript{f}, Jessica Ross, BS\textsuperscript{c}, Michael D. Swartz, PhD\textsuperscript{c}, Ashraf Yaseen, PhD\textsuperscript{c}, Steven H. Kelder, PhD, MPH\textsuperscript{f}, Shiming Zhang, MS\textsuperscript{c}, Onyinye S Omega-Njemnobi, MD, PhD\textsuperscript{d}, Michael O. Gonzalez, MPH\textsuperscript{c}, Leqing Wu, MS\textsuperscript{c}, Eric Boerwinkle, PhD\textsuperscript{c}, David Lakey, M\textsuperscript{g}, Jennifer A. Shuford, MD\textsuperscript{h}, Stephen J. Pont, MD\textsuperscript{h}

Affiliations: \textsuperscript{a}The University of Texas Health Science Center at Houston, School of Public Health in Dallas, Dallas, TX, USA; \textsuperscript{b}Center for Pediatric Population Health, The University of Texas Health Science Center at Houston, School of Public Health and Children’s Health System of Texas, Dallas, TX, USA; \textsuperscript{c}The University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA; \textsuperscript{d}The University of Texas Health Science Center at Houston, School of Public Health in Austin, Austin, TX, USA; \textsuperscript{e}University of Texas at Austin, Austin, TX, USA; \textsuperscript{f}The University of Texas Health Science Center at Houston, School of Public Health in Brownsville, Brownsville, TX, USA; \textsuperscript{g}The University of Texas System, Austin, TX, USA; \textsuperscript{h}Texas Department of State Health Services, Austin, TX, USA

Address correspondence to: Sarah E. Messiah, The University of Texas Health Science Center at Houston, School of Public Health in Dallas, 2777 N Stemmons Fwy, Dallas, TX (Sarah.E.Messiah@uth.tmc.edu), 972-546-2919

The authors have withdrawn this manuscript for the following reasons:

1. Our latest analysis (mid-February, 2022) that includes the addition of 59 children with 3 completed timepoints shows a decrease in N antibodies at T2, versus this preprint that showed an increase in N antibodies from T1 to T2.

2. This preprint did not include those infected with the Omicron variant, which has had a substantial impact on the increase in pediatric infections and has important implications for antibody durability moving forward as such.

Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.